Previous 10 | Next 10 |
Summary Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomics and immunology, new diagnostics and surgeries, and reductions in stigma...
Summary TAMS for Non-Alcoholic Steatohepatitis NASH after topline PH2a results and what it could mean to Cytodyn long term investors. Wall Street modeling of non-revenue generating biotechs. Headwinds and risks involved. Overview CytoDyn Inc. (CYDY) is a Vanc...
Summary Toripalimab approval will be decided for Coherus at the end of December. Cimerli approval has pushed up the stock. However, the tori PDUFA is the major catalytic event here. It is interesting to see that despite its foray into original R&D through a Chine...
Alnylam is rapidly becoming the leader in ATTR through its successful therapy, patisiran. Intellia has presented data showing even deeper reductions in TTR. Though early Intellia has the potential to show better clinical outcomes in patients with ATTR. For years, patient...
Both the FY 2022 top line and bottom line for CSL didn't meet the market's expectations, with the weakness associated with the core Behring business segment being a key factor. The FY 2023 outlook for CSL is better than management guidance suggested, taking into account one-off items....
ImmunoGen announced that it will receive the FDA decision for mirvetuximab on November 28th. The deal with Oxford BioTechnologies will support further growth. ImmunoGen remains robust from a financial point of view. Two weeks ago, the leading biotech company ImmunoGen, I...
Results for both studies from the DISSOLVE phase 3 program, using SEL-212 for the treatment of patients with chronic refractory gout, are expected in Q1 of 2023. Potential to restore immune tolerance and target underlying cause of patients with primary biliary cirrhosis with use of Im...
Funding difficulties have definitely been priced into Clovis' share price. Clovis, though, has some interesting readouts due this year and in early 2023. If data is encouraging and new funding is announced, CLVS stock could rally sharply from present levels. Intro ...
After the FDA provided an update on the agency's response to the monkeypox outbreak on July 29th, investors misunderstood the FDA's statements, and the stock sold off 33% and shortly reverted. SIGA's monkeypox treatment TPOXX is already approved in the U.S., EU, and Canada for smallpo...
Today, we take a look at Adicet Bio for the first time. The company is pioneering what it hopes will be among the next wave of CAR-T therapies and is advancing its lead candidate. An investment analysis follows in the paragraphs below. Don't live the same year 75 tim...
News, Short Squeeze, Breakout and More Instantly...
ProShares Ultra Nasdaq Biotechnology Company Name:
BIB Stock Symbol:
NASDAQ Market:
2024-05-19 12:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-04-19 23:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-31 02:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...